Quick Answer
TScan Therapeutics, Inc. reported Long-Term Debt of $32.53 million for fiscal year 2025.
TScan Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $32.53M | +1.4% |
| 2024 | $32.07M | +20.1% |
| 2023 | $26.70M | -8.8% |
| 2022 | $29.29M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $32.41M | +5.8% | +0.4% |
| June 30, 2025 | $32.30M | +60.6% | +0.4% |
| March 31, 2025 | $32.18M | +37.2% | +0.3% |
| December 31, 2024 | $32.07M | +20.1% | +4.6% |
| September 30, 2024 | $30.65M | +6.3% | +52.4% |
| June 30, 2024 | $20.11M | -32.3% | -14.2% |
| March 31, 2024 | $23.45M | -20.5% | -12.2% |
| December 31, 2023 | $26.70M | -8.8% | -7.4% |
- TScan Therapeutics, Inc. showed an increase of +1.4% in Long-Term Debt compared to the prior fiscal year.
- Over the 2022–2025 period, TScan Therapeutics, Inc.’s long-term debt has grown by 11.1% (from $29.29 million to $32.53 million).
- The most recent figure is from TScan Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: